Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Havlik

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Biochemical Pharmacology|October 26, 2007
JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytesZdenek Dvorak, Radim Vrzal, Pavla Henklova, et al.
World Journal of Gastroenterology|November 1, 2017
Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literatureMartin Lovecek, Pavel Skalicky, Josef Chudacek, et al.
Cancer Gene Therapy|March 16, 2002
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinomaNagy Habib, Hosny Salama, Ahmed Abd El Latif Abu Median, et al.
Cancer Management and Research|January 23, 2019
Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterationsMartin Lovecek, Marketa Janatova, Pavel Skalicky, et al.
Oncology Letters|November 9, 2017
Dysregulation of KRAS signaling in pancreatic cancer is not associated with <i>KRAS</i> mutations and outcomeRadmila Lemstrova, Veronika Brynychova, David J Hughes, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Biochemical Pharmacology|October 26, 2007
JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytesZdenek Dvorak, Radim Vrzal, Pavla Henklova, et al.
World Journal of Gastroenterology|November 1, 2017
Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literatureMartin Lovecek, Pavel Skalicky, Josef Chudacek, et al.
Cancer Gene Therapy|March 16, 2002
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinomaNagy Habib, Hosny Salama, Ahmed Abd El Latif Abu Median, et al.
Cancer Management and Research|January 23, 2019
Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterationsMartin Lovecek, Marketa Janatova, Pavel Skalicky, et al.
Oncology Letters|November 9, 2017
Dysregulation of KRAS signaling in pancreatic cancer is not associated with <i>KRAS</i> mutations and outcomeRadmila Lemstrova, Veronika Brynychova, David J Hughes, et al.
Pageof 2